Hu-manity.co, the company championing the 31st Human Right for individuals to own their data as property, announces Dr. Dan Karlin as its new industry transformation officer (ITO). The ITO will help the pharmaceutical industry fully take advantage of the benefits of receiving explicitly consented human data.
“I am excited about showcasing how explicitly consented data can help drive better and more efficient research, to more quickly get drugs that work in the hands of patients,” says Karlin. He envisions a world where real world data converges on clinical trials data, unlocking the potential to understand the complexities of disease and health more completely. Karlin goes on to say, “I am eager to be part of a company that has a credo aligning its goals to the betterment of the citizens of the world.”
Karlin is a trusted operator in the healthcare industry. His strengths range from a deep understanding of pharmaceutical development as Pfizer’s former Head of Clinical, Informatics, and Regulatory Strategy for Digital Medicine; technology as Director of Biotech Ventures for CEAi; clinical experience in his time as Founder and Chief Medical Officer with Column Health; and academic medicine as an Assistant Professor of Psychiatry at Tufts University.
“We have experienced a rush of in-bound interest in our movement and the benefits it would bring,” says Michael DePalma, founder, president and COO of Hu-manity.co. DePalma explains, “Dan is that bridge that makes us better instantly by effectively connecting the dots for the pharmaceutical industry.”
To access more business news, visit NJB News Now.
Related Articles: